Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CDXS NASDAQ:GERN NASDAQ:RGLS NASDAQ:ZBIO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCDXSCodexis$2.41-4.0%$2.82$1.90▼$6.08$246.43M2.541.29 million shs1.45 million shsGERNGeron$1.40-4.8%$1.35$1.09▼$4.83$893.22M0.639.11 million shs9.03 million shsRGLSRegulus Therapeutics$8.16$8.10$0.83▼$8.35$564.92M0.351.02 million shsN/AZBIOZenas BioPharma$17.14-2.2%$14.38$5.83▼$26.25$673.77MN/A155,070 shs261,572 shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCDXSCodexis-3.98%-9.74%-15.14%+6.64%-15.44%GERNGeron-4.76%-0.71%+15.70%-10.26%-68.18%RGLSRegulus Therapeutics0.00%0.00%0.00%+0.74%+419.75%ZBIOZenas BioPharma-2.17%+2.57%+1.96%+78.36%+1,713,999,900.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCDXSCodexis3.8566 of 5 stars3.33.00.02.52.71.70.6GERNGeron3.2074 of 5 stars3.31.00.01.32.51.70.6RGLSRegulus TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AZBIOZenas BioPharma1.6505 of 5 stars3.50.00.00.02.10.80.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCDXSCodexis 2.50Moderate Buy$11.00356.43% UpsideGERNGeron 2.56Moderate Buy$4.19199.11% UpsideRGLSRegulus Therapeutics 2.17Hold$8.807.84% UpsideZBIOZenas BioPharma 3.00Buy$36.67113.92% UpsideCurrent Analyst Ratings BreakdownLatest CDXS, GERN, RGLS, and ZBIO Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/10/2025GERNGeronThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageSell$1.00(Data available from 9/4/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCDXSCodexis$59.35M3.67N/AN/A$0.62 per share3.89GERNGeron$76.99M11.60N/AN/A$0.41 per share3.41RGLSRegulus TherapeuticsN/AN/AN/AN/A$1.17 per shareN/AZBIOZenas BioPharma$5M144.35N/AN/A$5.69 per share3.01Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCDXSCodexis-$65.28M-$0.83N/AN/AN/A-113.67%-105.83%-46.06%10/30/2025 (Estimated)GERNGeron-$174.57M-$0.13N/AN/AN/A-53.52%-31.37%-16.01%11/6/2025 (Estimated)RGLSRegulus Therapeutics-$46.36M-$0.73N/AN/AN/AN/A-57.53%-53.26%N/AZBIOZenas BioPharma-$156.99M-$3.55N/A∞N/AN/A-59.21%-50.56%11/11/2025 (Estimated)Latest CDXS, GERN, RGLS, and ZBIO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/13/2025Q2 2025CDXSCodexis-$0.17-$0.16+$0.01-$0.16$14.18 million$15.33 million8/12/2025Q2 2025ZBIOZenas BioPharma-$1.02-$1.25-$0.23-$1.25$5.00 millionN/A8/6/2025Q2 2025GERNGeron-$0.03-$0.02+$0.01-$0.02$47.30 million$49.04 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCDXSCodexisN/AN/AN/AN/AN/AGERNGeronN/AN/AN/AN/AN/ARGLSRegulus TherapeuticsN/AN/AN/AN/AN/AZBIOZenas BioPharmaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCDXSCodexis0.715.825.70GERNGeron0.467.876.79RGLSRegulus TherapeuticsN/A16.3116.31ZBIOZenas BioPharmaN/A5.235.23Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCDXSCodexis78.54%GERNGeron73.71%RGLSRegulus Therapeutics92.38%ZBIOZenas BioPharmaN/AInsider OwnershipCompanyInsider OwnershipCDXSCodexis1.90%GERNGeron7.42%RGLSRegulus Therapeutics4.35%ZBIOZenas BioPharma16.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCDXSCodexis25090.27 million88.55 millionOptionableGERNGeron70638.02 million590.68 millionOptionableRGLSRegulus Therapeutics3069.23 million66.22 millionOptionableZBIOZenas BioPharmaN/A42.11 million35.16 millionN/ACDXS, GERN, RGLS, and ZBIO HeadlinesRecent News About These CompaniesStrategic Funding Boost: Zenas BioPharma’s Partnership with Royalty Pharma Enhances Obexelimab’s Commercial PotentialSeptember 3 at 6:30 AM | tipranks.comZenas BioPharma Secures $300M Funding for ObexelimabSeptember 2 at 7:51 AM | tipranks.comZenas BioPharma and Royalty Pharma Enter into Obexelimab Funding Agreement for up to $300 MillionSeptember 2 at 7:05 AM | globenewswire.comZenas BioPharma, Inc. $ZBIO Shares Sold by Wellington Management Group LLPAugust 31, 2025 | marketbeat.comZenas BioPharma to Present at Upcoming Healthcare Investor ConferencesAugust 26, 2025 | globenewswire.comZenas BioPharma (NASDAQ:ZBIO) Trading Down 7.2% - Here's What HappenedAugust 21, 2025 | marketbeat.comWe Think Zenas BioPharma (NASDAQ:ZBIO) Needs To Drive Business Growth CarefullyAugust 20, 2025 | finance.yahoo.comZenas BioPharma (NASDAQ:ZBIO) Trading 8.1% Higher - Should You Buy?August 20, 2025 | marketbeat.comHC Wainwright Lowers Earnings Estimates for Zenas BioPharmaAugust 17, 2025 | marketbeat.comWhat is Wedbush's Estimate for Zenas BioPharma Q3 Earnings?August 17, 2025 | marketbeat.comZenas BioPharma (NASDAQ:ZBIO) Rating Lowered to Sell at Wall Street ZenAugust 17, 2025 | marketbeat.comZenas BioPharma (ZBIO) Expected to Announce Quarterly Earnings on ThursdayAugust 15, 2025 | marketbeat.comZenas BioPharma (NASDAQ:ZBIO) Issues Earnings ResultsAugust 14, 2025 | marketbeat.comZenas BioPharma Faces Legal and Financial Challenges Amid Securities Class Action LawsuitAugust 13, 2025 | msn.comZenas BioPharma Reports Q2 2025 Financial ResultsAugust 13, 2025 | tipranks.comZenas BioPharma expects cash to fund operations into Q4 of 2026August 12, 2025 | msn.comZenas BioPharma reports Q2 EPS ($1.25) vs ($24.23) last yearAugust 12, 2025 | msn.comZenas BioPharma Reports Second Quarter 2025 Financial Results and Provides Corporate UpdatesAugust 12, 2025 | globenewswire.com44,067 Shares in Zenas BioPharma, Inc. (NASDAQ:ZBIO) Purchased by Jefferies Financial Group Inc.August 9, 2025 | marketbeat.comZenas BioPharma (NASDAQ:ZBIO) Stock Price Down 8.8% - Should You Sell?August 6, 2025 | marketbeat.comZenas BioPharma (NASDAQ:ZBIO) Stock Price Up 10.2% - What's Next?August 5, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCDXS, GERN, RGLS, and ZBIO Company DescriptionsCodexis NASDAQ:CDXS$2.41 -0.10 (-3.98%) Closing price 09/3/2025 04:00 PM EasternExtended Trading$2.42 +0.00 (+0.21%) As of 09/3/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Codexis, Inc. discovers, develops, and sells enzymes and other proteins. The company operates through two segments, Performance Enzymes and Novel Biotherapeutics. It offers biocatalyst products and services. The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver, a technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes. The company's platform is also used for molecular biology and in vitro diagnostic enzymes. It has a collaboration agreement with Nestlé Health Science to develop CDX-7108 for the treatment of exocrine pancreatic insufficiency. The company sells its products to pharmaceutical manufacturers through its direct sales and business development force in the United States and Europe. The company was incorporated in 2002 and is headquartered in Redwood City, California.Geron NASDAQ:GERN$1.40 -0.07 (-4.76%) Closing price 09/3/2025 04:00 PM EasternExtended Trading$1.42 +0.02 (+1.36%) As of 05:19 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.Regulus Therapeutics NASDAQ:RGLSRegulus Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease. The company is also developing a pipeline of preclinical drug products for target organ-selective delivery strategies. Regulus Therapeutics Inc. was incorporated in 2007 and is headquartered in San Diego, California.Zenas BioPharma NASDAQ:ZBIO$17.14 -0.38 (-2.17%) As of 09/3/2025 04:00 PM EasternZenas BioPharma, Inc. is a clinical-stage global biopharmaceutical company, which engages in the development and commercialization of transformative immunology-based therapies for patients. The company was founded by Lonnie O. Moulder Jr on November 12, 2019 and is headquartered in Waltham, MA. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Zscaler Shares Can Hit a Fresh High Before Year-End Why Qualcomm Is Outperforming NVIDIA After Months of Lagging Alphabet Stock Surges After Dodging Harsh Antitrust Remedies Wall Street Punishes Dell's Record Quarter: Why They Are Wrong Taiwan Semiconductor Falls on China News—Buy The Dip? CrowdStrike Tests $412 Support as Options Traders Turn Bullish What to Expect From the Q3 Reporting Season IREN Is Up 186% YTD on AI Pivot—And It’s Just Getting Started Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
